Study of Safety of Foradil in Patients With Persistent Asthma

A 26 Week, Randomized, Active-controlled Safety Study of Double-blind Formoterol Fumarate in Free Combination With an Inhaled Corticosteroid Versus an Inhaled Corticosteroid in Adolescent and Adult Patients With Persistent Asthma.

The purpose of this study was to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, asthma related intubations, and asthma related deaths) in adolescents and adults (12 years of age and older) taking inhaled formoterol fumarate/fluticasone propionate combination was the same as those taking inhaled fluticasone propionate alone.

Study Overview

• Status: Terminated
• Conditions: Persistent Asthma
• Intervention / Treatment: Drug: Formoterol 12 mcg; Drug: Fluticasone propionate 100 mcg; Drug: Fluticasone propionate 250 mcg; Drug: Fluticasone propionate 500 mcg; Drug: Placebo

Detailed Description

This was a 26 week, double blind, randomized, active-controlled safety study of Foradil in free combination with inhaled corticosteroid versus an inhaled corticosteroid alone in adults and adolescent patients with persistent asthma. The primary objective of the study was to demonstrate that the addition of formoterol fumarate to fluticasone propionate is non-inferior to fluticasone propionate alone in terms of the risk of composite serious asthma related events (asthma-related hospitalization, asthma-related intubation, and asthma-related death). The individual components of the composite primary endpoint (i.e., asthma-related hospitalization, asthma-related intubation and asthma-related death) will be assessed as a secondary safety endpoints.

The efficacy assessment is the secondary objective.

• Study Type: Interventional
• Enrollment (Actual): 827
• Phase: Phase 4

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Avondale, Arizona, United States, 85323
      • Novartis Investigative Site
  • California
    • North Hollywood, California, United States, 91606
      • Novartis Investigative Site
  • Florida
    • Bradenton, Florida, United States, 34209
      • Novartis Investigative Site
    • Miami, Florida, United States, 33126
      • Novartis Investigative Site
    • Miami, Florida, United States, 33134
      • Novartis Investigative Site
  • Georgia
    • Conyers, Georgia, United States, 30012
      • Novartis Investigative Site
    • Stone Mountain, Georgia, United States, 30083
      • Novartis Investigative Site
  • Kentucky
    • Louisville, Kentucky, United States, 40214
      • Novartis Investigative Site
    • Louisville, Kentucky, United States, 40220
      • Novartis Investigative Site
  • Louisiana
    • Covington, Louisiana, United States, 70433
      • Novartis Investigative Site
  • Maryland
    • Baltimore, Maryland, United States, 21287
      • Novartis Investigative Site
    • Gaithersburg, Maryland, United States, 20878
      • Novartis Investigative Site
  • Mississippi
    • Picayune, Mississippi, United States, 39466
      • Novartis Investigative Site
  • Missouri
    • Saint Louis, Missouri, United States, 63117
      • Novartis Investigative Site
    • Saint Louis, Missouri, United States, 63128
      • Novartis Investigative Site
  • New York
    • North Massapequa, New York, United States, 11758
      • Novartis Investigative Site
  • North Carolina
    • Elizabeth City, North Carolina, United States, 27909
      • Novartis Investigative Site
    • Winston Salem, North Carolina, United States, 27103
      • Novartis Investigative Site
  • Ohio
    • Cleveland, Ohio, United States, 44106-5000
      • Novartis Investigative Site
  • Pennsylvania
    • Oaks, Pennsylvania, United States, 19456
      • Novartis Investigative Site
  • Rhode Island
    • East Greenwich, Rhode Island, United States, 02818
      • Novartis Investigative Site
  • South Carolina
    • Mount Pleasant, South Carolina, United States, 29464
      • Novartis Investigative Site
  • Tennessee
    • Memphis, Tennessee, United States, 38118
      • Novartis Investigative Site
  • Texas
    • Dallas, Texas, United States, 75235
      • Novartis Investigative Site
  • Utah
    • Saint George, Utah, United States, 84790
      • Novartis Investigative Site
  • Wisconsin
    • Mequon, Wisconsin, United States, 53092
      • Novartis Investigative Site
    • Milwaukee, Wisconsin, United States, 53172
      • Novartis Investigative Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 12 years and older (ADULT, OLDER_ADULT, CHILD)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Key Inclusion Criteria:

1. Written informed consent, and assent if applicable, must be obtained before any assessment is performed.
2. Male or female patients 12 years of age and older
3. Confirmed diagnosis of persistent asthma, as defined by national and international asthma guidelines (e.g., GINA; NIH; etc.) for at least 1 year prior to study enrollment.
4. PEF≥50% of predicted normal value.
5. Current and appropriate use of one of the treatments listed in the protocol for asthma.

6. Recent asthma exacerbation between 30 days and 12 months prior to randomization that either:

   • required treatment with systemic corticosteroids (tablets, suspension, or injection) or
   • required hospitalization (defined as an inpatient stay or >24-hour stay in an observation area in an emergency room or other equivalent facility)

Key Exclusion Criteria:

1. History of life-threatening asthma episode that required intubation and/or was associated with hypercapnia requiring non-invasive ventilatory support.
2. Current evidence of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, allergic bronchopulmonary aspergillosis, cystic fibrosis, bronchopulmonary dysplasia, or other respiratory abnormalities other than asthma.
3. Current evidence of, or past physician assessment of, chronic bronchitis, emphysema, or chronic obstructive pulmonary disease.
4. History of smoking ≥ 10 pack years.
5. Exercise induced asthma (as the only asthma-related diagnosis) not requiring daily asthma control medicine.
6. Suspected or documented bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved at randomization.
7. Worsening/Unstable asthma within 7 days prior to randomization.
8. Any asthma exacerbation requiring systemic corticosteroids within 30 days of randomization or more than 4 separate exacerbations in the 12 months preceding randomization.
9. Two or more hospitalizations for greater than 24 hours duration for treatment of asthma in the 12 months preceding randomization.
10. History of hypersensitivity to any beta2-agonist, sympathomimetic drug, inhaled corticosteroids, or systemic corticosteroid therapy or any component of the possible study treatments in this trial, including severe milk protein hypersensitivity.
11. Use of anti-IgE (e.g., omalizumab) or any other monoclonal antibody, in the 6 months prior to randomization.
12. Use of (Beta) β-blockers within 1 day prior to first dose of study medication.
13. Use of ICS, LABA, ICS+LABA, LTRAs, leukotriene modifiers, anticholinergics, or theophylline must be discontinued prior to the first dose of investigational treatment.
14. Use of a potent CYP3A4 inhibitor within 4 weeks of randomization (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: FOM 12 mcg + FP; Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation	Drug: Formoterol 12 mcg; Formoterol 12 mcg one inhalation twice daily, via dry powder inhaler; Other Names: FOR258; Drug: Fluticasone propionate 100 mcg; Fluticasone propionate 100 mcg one inhalation twice daily via dry powder inhaler; Drug: Fluticasone propionate 250 mcg; Fluticasone propionate 250 mcg one inhalation twice daily via dry powder inhaler; Drug: Fluticasone propionate 500 mcg; Fluticasone propionate 500 mcg, one inhalation twice daily via dry powder inhaler
ACTIVE_COMPARATOR: fluticasone propionate (FP); fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation	Drug: Fluticasone propionate 100 mcg; Fluticasone propionate 100 mcg one inhalation twice daily via dry powder inhaler; Drug: Fluticasone propionate 250 mcg; Fluticasone propionate 250 mcg one inhalation twice daily via dry powder inhaler; Drug: Fluticasone propionate 500 mcg; Fluticasone propionate 500 mcg, one inhalation twice daily via dry powder inhaler; Drug: Placebo; Placebo to match formoterol one inhalation twice daily via dry powder inhaler

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of First Occurrence(s) of Any Composite Endpoint Including Asthma-related Hospitalizations, Intubations and Deaths During the Study at 26 Weeks	The primary safety endpoint was the number of first occurrence(s) of any composite endpoint. The composite events include asthma-related deaths, asthma-related intubations and asthma-related hospitalizations. The number of events includes all adjudication confirmed events, one patient could experience multiple events during the course of study; Event rate = 100 * n patients with any events / total N patients in treatment group.	26 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Asthma Exacerbations at 26 Weeks	Number of asthma exacerbations events	26 weeks
Percentage of Days of School/Work Missed at 26 Weeks	The percentage of days of school/work missed during the treatment period (26 weeks). Overall percentage of school days missed for each student patient or of work days missed is calculated by total number of days missed divided by total days of treatment.	26 weeks
Percentage of Days With Limited Ability to Perform Normal Daily Activities at 26 Weeks	The percentage of days with limited ability to perform normal daily activities during the treatment period (26 weeks). Percentage is calculated as total number of days when the patient had limited ability to perform normal daily activities divided by total days of treatment.	26 weeks
Percentage of Days With Nighttime Awakenings at 26 Weeks	Percentage of days with nighttime awakenings during the treatment period (26 weeks)	26 weeks
Percentage of Days With no Rescue Medication Use at 26 Weeks	Percentage of rescue free days is calculated as total number of days with no rescue medication was taken divided by total days of treatment.	26 weeks
Percentage of Days With no Symptoms at 26 Weeks	Percentage of days with no symptoms during the treatment period (26 weeks). Percentage is calculated as total number of days with no symptoms divided by total days of treatment.	26 weeks
Change From Baseline in Asthma Control Questionnaire (ACQ - 6) Total Score at Week 26	Change from baseline in Asthma control Questionnaire (ACQ - 6) total score at week 26. Results of the Asthma control questionnaire (ACQ-6); The average score of the six questions is calculated as the sum of scores divided by the number of questions that were answered at the time point, as long as there were at least 4 questions answered. The ACQ6 score is calculated as the mean of the responses to the first 6 questions of the ACQ. The ACQ is a scale containing 7 questions, each question has a 7-point scale which ranges from 0 to 6; a total score of 0 corresponds to no impairment and a total score of 6 corresponds to maximum impairment.	baseline and 26 weeks
Unplanned Healthcare Utilization at Visit 3 (Week 4), Visit 4 (Week 12) and Visit 5 (Week 26)	Unplanned healthcare utilization by visit (Telephone contact with study doctor (MD); Telephone contact with other physician (MD) or healthcare provider (HCP); Unscheduled or unplanned visit to study doctor (including home visits); Unscheduled or unplanned visit to other physician or healthcare provider (including home visits); Emergency department or hospital visit (< 24 hours); Hospital admission or Emergency department visit (> 24 hours).	Week 4, Week 12, and Week 26

Collaborators and Investigators

• Sponsor: Novartis Pharmaceuticals
• Investigators: Study Director: Chrsitopher Compton, Novartis Pharmaceuticals

Study record dates

Study Major Dates

• Study Start: May 1, 2013
• Primary Completion (ACTUAL): May 1, 2016
• Study Completion (ACTUAL): May 1, 2016

Study Registration Dates

• First Submitted: April 22, 2013
• First Submitted That Met QC Criteria: April 29, 2013
• First Posted (ESTIMATE): May 3, 2013

Study Record Updates

• Last Update Posted (ACTUAL): March 21, 2017
• Last Update Submitted That Met QC Criteria: January 30, 2017
• Last Verified: January 1, 2017

More Information

Terms related to this study

• Keywords: Asthma; safety; Foradil; fluticasone propionate; inhaled corticosteroid; formoterol fumarate
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Immune System Diseases; Lung Diseases; Hypersensitivity, Immediate; Bronchial Diseases; Lung Diseases, Obstructive; Respiratory Hypersensitivity; Hypersensitivity; Asthma; Physiological Effects of Drugs; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Anti-Inflammatory Agents; Adrenergic Agonists; Dermatologic Agents; Bronchodilator Agents; Anti-Asthmatic Agents; Respiratory System Agents; Anti-Allergic Agents; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Fluticasone; Xhance; Formoterol Fumarate
• Other Study ID Numbers: CFOR258D2416; 2012-004854-27 (EUDRACT_NUMBER)